drugset / Trial / NCT00469599
Treatment of Secondary Hyperparathyroidism in the Uremic Patient
RandomizedCrossoverOpen-labelTreatment
Summary
The purpose of this study is to compare alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients.
Timeline
- Start
- 2007-07
- Primary completion
- 2010-09
- Completion
- 2010-10
Publications
- Hansen D, Rasmussen K, Rasmussen LM, Bruunsgaard H, Brandi L. The influence of vitamin D analogs on calcification modulators, N-terminal pro-B-type natriuretic peptide and inflammatory markers in hemodialysis patients: a randomized crossover study. BMC Nephrol. 2014 Aug 12;15:130. doi: 10.1186/1471-2369-15-130.
- Hansen D, Brandi L, Rasmussen K. Treatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol. BMC Nephrol. 2009 Sep 24;10:28. doi: 10.1186/1471-2369-10-28.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Alfacalcidol | Other / unclassified | 1 ug | Intravenous |
| Comparator | Paricalcitol | Other / unclassified | 3 ug | Intravenous |